

Executive Corridor
Darlington Memorial Hospital
Hollyhurst Road
Darlington
DL3 6HX
Switchboard Tel: 01325 38 0100
Foundation Trust Office: 01325 74 3625
Corporate Records Office: 01325 74 3700

Request for Information Reference: 04.22.03

FOI Direct line: 01325 743700
Email: cdda-tr.cddftfoi@nhs.net

Email only

6th April 2022

Freedom of Information Act 2000 – Request for Information

Thank you for submitting a request for information which we received on 1st April 2022 in relation to County Durham and Darlington NHS Foundation Trust (the Trust). Your request has been processed under the provisions of the Freedom of Information Act 2000 and I am now able to provide you with a response.

Your request was in relation to Breast cancer treatment and I am providing the following information in response to your specific questions:

1. In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with:

- **Abemaciclib (Verzenios) + aromatase inhibitor *** - 0
- **Abemaciclib (Verzenios) + Fulvestrant (Faslodex)** - 8
- **Alpelisib (Piqray) + Fulvestrant (Faslodex)** - 0
- **Atezolizumab (Tecentriq)**** - 0
- **Bevacizumab (Avastin)** - 0
- **Eribulin (Halaven)** - 2
- **Everolimus (Afinitor) + Exemestane** - 0
- **Fulvestrant (Faslodex) as a single agent** - 0
- **Gemcitabine + paclitaxel** - 0
- **Herceptin (Trastuzumab) + paclitaxel** - 0
- **Herceptin (Trastuzumab) as a single agent** - 0
- **Lapatinib (Tyverb)** - 0
- **Neratinib (Nerlynx)** - 0
- **Olaparib (Lynparza)** - 0
- **Palbociclib (Ibrance) + aromatase inhibitor*** - 23
- **Palbociclib (Ibrance) + Fulvestrant (Faslodex)** - 40
- **Pertuzumab (Perjeta) + trastuzumab + docetaxel** - 0
- **Ribociclib (Kisqali) + aromatase inhibitor*** - 0

- **Ribociclib (Kisqali) + Fulvestrant (Faslodex)** - 0
- **Talazoparib (Talzenna)** - 4
- **Trastuzumab emtansine (Kadcyla)** - 5
- **Other active systemic anti-cancer therapy ****

Capectiabine	- 18
Denosumab	- 79
EC90	- 1
Evrolimus	- 3
Gemcitiabine + Carboplatin	- 2
Pactiltaxel	- 21
PHESGO	- 9
PHESGO + Docetaxel	- 5
Vinorelbine	- 5

***aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole**

****eg. docetaxel, vinorelbine or capecitabine as a single agent**

2. For the above patients, how many of these received their first ever dose for each product line?

For Question 2 the Trust can only look at who is a new C1 patient. Unfortunately this may include some patients who are receiving the treatments as a second line of treatment (e.g. not a new patient).

ABEMACICLIB + FULVESTRANT	4
CAPECITABINE	2
DENOSUMAB	14
ERIBULIN	1
EVEROLIMUS	1
GEMCITABINE + CARBOPLATIN	1
PACLITAXEL	12
PALBOCICLIB + FULVESTRANT	6
PALBOCICLIB + LETROZOLE	2
PHESGO + DOCETAXEL	3
VINORELBINE	3
Grand Total	49

In line with the Information Commissioner’s directive on the disclosure of information under the Freedom of Information Act 2000 your request will form part of our disclosure log on the Trust’s website. However please be assured that we anonymise all responses prior to adding them to the disclosure log.

I hope that this response has provided you with the information you had requested. If you have any queries or wish to discuss the information supplied, please do not hesitate to contact me by telephone or in writing. If however, you are dissatisfied with the way in which your request has been handled and would like an internal review, you will need to contact me in writing at the above address or via cdda-tr.cddftfoi@nhs.

If you remain dissatisfied with our response following an internal review you have the right to appeal to The Information Commissioner at Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF. More information is available on their website; www.ico.gov.uk.

Yours sincerely

Corporate Records and Freedom of Information Facilitator